Sharon Yaqoob-Krysztofiak (pictured here with Dr. Andrew Arnold) co-authored “Investigating the in Vivo Role of an Activating GCM2 Variant, I383M, as a Potential Contributor to the Pathogenesis of Primary Hyperparathyroidism” at the July 2025 Endocrine Society Annual Meeting in San Francisco, CA.

Posted on by Leslin A Vinton

Sharon Yaqoob-Krysztofiak (pictured here with Dr. Andrew Arnold) co-authored “Investigating the in Vivo Role of an Activating GCM2 Variant, I383M, as a Potential Contributor to the Pathogenesis of Primary Hyperparathyroidism” at the July 2025 Endocrine Society Annual Meeting in San Francisco, CA.

Sharon Yaqoob-Krysztofiak (pictured here with Dr. Andrew Arnold) co-authored “Investigating the in Vivo Role of an Activating GCM2 Variant, I383M, as a Potential Contributor to the Pathogenesis of Primary Hyperparathyroidism” at the July 2025 Endocrine Society Annual Meeting in San Francisco, CA.